Study on the application of pelvic bone marrow-sparing volumetric modulated arc therapy in concurrent chemoradiotherapy for cervical cancer patients

This study investigated the dosimetric, hematologic toxicity (HT), and clinical efficacy benefits of pelvic bone marrow-sparing volumetric modulated arc therapy (PBMS-VMAT) in cervical cancer patients undergoing concurrent chemoradiotherapy (CCRT). Between October 2023 and March 2024, 244 cervical cancer patients undergoing CCRT were enrolled and classified into the PBMS-VMAT group or the control group. The PBMS-VMAT group received additional pelvic bone marrow (BM) dose-volume constraints. Dosimetric parameters, acute HT, and preliminary clinical efficacy were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for grade 2 or higher (G2 + ) HT. Dynamic changes in lymphocyte counts were also evaluated. There were no statistically significant differences in target-volume dosimetric parameters between the two groups. However, PBMS-VMAT significantly reduced pelvic BM V 10 , V 20 , and V 40 values, while no significant differences were observed in bladder, rectum, bowel, or femoral head dosimetry. G2 + HT was significantly lower in the PBMS-VMAT group (51.6% vs. 73.0%; 95% CI : − 37.8% to − 4.0%; P = 0.014), and lymphocyte counts were higher during and after CCRT. The complete response rate was 61.48% in the PBMS-VMAT group versus 48.36% in the control group (95% CI : 0.86%–24.38%; P = 0.04). Among all variables examined, V 10 remained the only factor independently associated with HT (odds ratio 1.16; 95% CI : 1.07–1.26; P < 0.001). PBMS-VMAT not only limits acute radiation-induced lymphopenia but also shortens the recovery window. In cervical cancer patients undergoing CCRT, PBMS-VMAT effectively protects bone marrow hematopoietic function while maintaining target dose coverage and satisfying organ-at-risk dose constraints. Thus, PBMS-VMAT may represent a superior radiotherapy technique for CCRT in cervical cancer and holds promise for broader clinical application.

Authors

Institutions

Publication Details

Journal
Journal of Cancer Research and Clinical Oncology
Published
2026-11-15
DOI
https://doi.org/10.1007/s00432-026-06666-8
Primary Topic
Advanced Radiotherapy Techniques
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Study on the application of pelvic bone marrow-sparing volumetric modulated arc therapy in concurrent chemoradiotherapy for cervical cancer patients

Mingfang Guo, Li Yin, Yue Huang, Na Zhang
1 links
Journal of Cancer Research and Clinical Oncology
Advanced Radiotherapy Techniques
article

Study on the application of pelvic bone marrow-sparing volumetric modulated arc therapy in concurrent chemoradiotherapy for cervical cancer patients

Mingfang Guo, Li Yin, Yue Huang, Na Zhang
article en

Abstract

This study investigated the dosimetric, hematologic toxicity (HT), and clinical efficacy benefits of pelvic bone marrow-sparing volumetric modulated arc therapy (PBMS-VMAT) in cervical cancer patients undergoing concurrent chemoradiotherapy (CCRT). Between October 2023 and March 2024, 244 cervical cancer patients undergoing CCRT were enrolled and classified into the PBMS-VMAT group or the control group. The PBMS-VMAT group received additional pelvic bone marrow (BM) dose-volume constraints. Dosimetric parameters, acute HT, and preliminary clinical efficacy were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for grade 2 or higher (G2 + ) HT. Dynamic changes in lymphocyte counts were also evaluated. There were no statistically significant differences in target-volume dosimetric parameters between the two groups. However, PBMS-VMAT significantly reduced pelvic BM V 10 , V 20 , and V 40 values, while no significant differences were observed in bladder, rectum, bowel, or femoral head dosimetry. G2 + HT was significantly lower in the PBMS-VMAT group (51.6% vs. 73.0%; 95% CI : − 37.8% to − 4.0%; P = 0.014), and lymphocyte counts were higher during and after CCRT. The complete response rate was 61.48% in the PBMS-VMAT group versus 48.36% in the control group (95% CI : 0.86%–24.38%; P = 0.04). Among all variables examined, V 10 remained the only factor independently associated with HT (odds ratio 1.16; 95% CI : 1.07–1.26; P < 0.001). PBMS-VMAT not only limits acute radiation-induced lymphopenia but also shortens the recovery window. In cervical cancer patients undergoing CCRT, PBMS-VMAT effectively protects bone marrow hematopoietic function while maintaining target dose coverage and satisfying organ-at-risk dose constraints. Thus, PBMS-VMAT may represent a superior radiotherapy technique for CCRT in cervical cancer and holds promise for broader clinical application.

Journal of Cancer Research and Clinical Oncology
Chongqing University (CN), Chongqing Cancer Hospital (CN)
Good health and well-being
Advanced Radiotherapy Techniques
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon